Under the comprehensive factors such as the difficulty in maintaining the long-term prosperity of the industry through GMP certification, pharmaceutical machinery enterprises have become the trend to maintain performance growth through transformation and increasing side businesses. According to Dongfulong's announcement, the company plans to invest a total of no more than 75 million yuan to acquire * Medical, which specializes in absorbable medical films, and to participate in Jianzhong Medical, which specializes in disposable medical packaging and sterilization infection control products. In February of this year, the company announced again that it plans to invest 8 million yuan to establish a joint venture subsidiary specializing in ureteral stents, catheters, and endoscopes. In this situation, the medical device field has become a breakthrough for these two companies to maintain performance growth.

Previously, Jin Jie, the Secretary of Qianshan Pharmaceutical Machinery, pointed out that the current ratio of patient medication costs to medical device costs in the domestic market is 1:0.2, while in developed countries in Europe and America, the ratio is 1:1. It is expected that there is still significant room for development in China's medical device market. Regarding this, a securities analyst stated that Qianshan Pharmaceutical Machinery and Dongfu are already two major sub industries of pharmaceutical machinery freeze-drying and injection,